ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК КАК ОСНОВА ПОВЫШЕННОГО РИСКА РАЗВИТИЯ ГЕМОРРАГИЧЕСКИХ И ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ: МЕСТО ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ
https://doi.org/10.18087/cardio.2018.4.10111
Аннотация
Об авторах
А. Г. Обрезан
ФГБОУ ВО «Санкт-Петербургский государственный университет»
Россия
Россия
А. Ю. Земченков
ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова» Минздрава России
Россия
Россия
Список литературы
1. Bobrov L. L., Gayvoronskaya V. V., Kulikov A. N. et al. Clinical pharmacology and pharmacotherapy of the internal diseases. St-Petersburg. 2000; 365 p. Russian (Бобров Л. Л., Гайворонская В. В., Куликов А. Н. и др. Клиническая фармакология и фармакотерапия внутренних болезней (методическое пособие). С.-Петербург. 2000; 365 с.)
2. National Russian Nephrology Society Work Group. National Recommendations. Chronic Kidney Disease: main statements, definition, diagnostics, screening, approaches to prophylaxis and treatment. St-Petersburg. 2012;52 p. Russian (Рабочая группа Научного общества нефрологов России. Национальные рекомендации. Хроническая болезнь почек: основные положения, определение, диагностика, скрининг, подходы к профилактике и лечению. Санкт-Петербург: Левша; 2012. 52 с.)
3. Cockcroft D. W., Gault M. H. Prediction of creatinine from serum creatinine. Nephron 1976;16 (1):31-41.
4. Levey A. S., Bosch J. P., Lewis J. B. A more accurate method to estimate glomerular filtration rate from serum creatinine; a new prediction equation. Ann Intern Med 1999;130 (8):461-470.
5. Hallan S., Asberg A., Lindberg M., Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004;44 (1):84-93.
6. Ma Y. C., Zuo L., Chen J. H. et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17 (10):2937-2944.
7. Zemchenkov A., Konakova I., Sabodash A. et al. Three-year pre-dialysis trajectories of eGFR decline before dialysis according to city CKD register data. Clinical Nephrology 2017 (2):4-11. Russian (Земченков А. Ю., Конакова И. Н., Сабодаш А. Б. и др. Трехлетние траектории снижения расчетной СКФ перед началом диализа по данным городского регистра пациентов с ХБП. Клиническая нефрология 2017; (2):4-11).
8. Zemchenkov A. Yu., Konakova I. N. The chronic kidney disease progression rates according to St.-Petersburg CKD register. Nephrology and Dialysis 2015;17 (1):34-51. Russian (Земченков А. Ю., Конакова И. Н. Темпы прогрессирования хронической болезни почек по данным Санкт-Петербургского городского регистра ХБП. Нефрология и диализ 2015;17 (1):34-51.)
9. Di Minno G., Cerbone A., Usberti M. et al. Platelet dysfunction in uremia, II: correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 1986;108:246-252.
10. Moal V., Brunet P., Dou L. et al. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dialysis Transplant 2003;18:1834-1841.
11. Kaw D., Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dialysis 2006;19:317-322.
12. Castillo R., Lozano T., Escolar G. et al. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 1986;68:337-342.
13. Sloand E. M., Sloand J. A., Prodouz K. et al. Reduction of platelet glycoprotein Ib in uremia. Br J Haematolol 1991;77:375-381.
14. Sloand J., Sloand E. Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 1997;8:799-803.
15. Lindahl T. L., Lundahl J., Netre C., Egberg N. Studies of the platelet fibrinogen receptor in Glanzmann patients and uremic patients. Thromb Res 1992;67:457-466.
16. Gawaz M. P., Dobos G., Spath M. et al. Impaired function of platelet membrane glycoprotein IIb/IIIa in end-stage renal disease. J Am Soc Nephrol 1994;5:36-46.
17. Sreedhara R., Itagaki I., Hakim R. M. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb/IIIa receptors. Am J Kidney Dis 1996;27:355-364.
18. Di Minno G., Martinez J., McKean M. L. et al. Platelet dysfunction in uremia: multifaceted defect partially corrected by dialysis. Am J Med 1985;79:552-559.
19. Eknoyan G., Brown C. H. D. Biochemical abnormalities of platelets in renal failure: evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1981;1:17-23.
20. Walkowiak B., Pawlowska Z., Michalak E., Cierniewski C. S. Expression of fibrinogen receptors on platelets of uremic patients is correlated with the content of GPIIb and plasma level of creatinine. Thromb Haemost 1994;71:164-168.
21. Remuzzi G., Benigni A., Dodesini P. et al. Reduced platelet thromboxane formation in uremia: evidence for a functional cyclooxygenase defect. J Clin Invest 1983;71:762-768.
22. Bonomini M., Dottori S., Amoroso L. et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004;2:1275-1281.
23. Ando M., Iwata A., Ozeki Y. et al. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002;62:1757-1763.
24. Vaziri N. D., Shah G. M., Winer R. L. et al. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989;53:173-180.
25. Irish A. B., Green F. R. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype. Nephrol Dial Transplant 1998;13:679-684.
26. Sorensen P.J., Nielsen A. H., Knudsen F., Dyerberg J. Further investigations of the defective protein C in hemodialysis, hemofiltration and continuous ambulatory peritoneal dialysis. Blood Purif 1989;7:218-222.
27. Faioni E. M., Franchi F., Krachmalnicoff A. et al. Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma. Thromb Haemost 1991;66:420-425.
28. Joist J. H., Remuzzi G., Mannucci P. M. Abnormal bleeding and thrombosis in renal disease. In: Colman R. W., Hirsh J., Marder V. J., Salzman E. W., eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: J. B. Lippincott; 1994:921-935.
29. Vaziri N. D., Gonzales E. C., Wang J., Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994;23:828-835.
30. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998;137:133-139.
31. Mercier E., Branger B., Vecina F. et al. Tissue factor coagulation pathway and blood cells activation state in renal insufficiency. Hematol J 2001;2:18-25.
32. Obrezan A. G., Skorodumova E. A., Kostenko V. A. et al. The effect of chronic kidney disease on the course of myocardial infarction in the hospital period. Vestnik of Saint-Petrsberg university. Medicine. 2014;4:50-55. Russian (Обрезан А. Г., Скородумова Е. А., Костенко В. А. и др. Влияние хронической болезни почек на течение инфаркта миокарда в госпитальном периоде. Вестник Санкт-Петербургского университета. Медицина 2014;4:50-55.)
33. Kostenko V. A., Skorodumova E. A., Obrezan A. G. et al. Multiple organ dysfunction abd systemic inflammation in acute cardiac decompensation - mutual influence on the clinical course and prognosis. Vestnik of Russian Military-medical academy 2015:49:54-58. Russian (Костенко В. А., Скородумова Е. А., Обрезан А. Г. и др. Полиорганная дисфункция и системное воспаление при острой сердечной декомпенсации - взаимовлияние на клиническое течение и прогноз. Вестник Российской Военно-Медицинской академии 2015:49:54-58).
34. Iguchi Y., Kimura K., Kobayashi K. Relation of atrial fibrillation to glomerular filtration rate. AmJ Cardiol 2008;102 (8):1056-1059.
35. Tsagalis G., Bakirtzi N., Manios E. et al. Atrial fibrillation in chronic hemodialysis patients: prevalence, types, predictors, and treatment practices in Greece. Artif Organs 2011;35:916-922.
36. Alonso A., Lopez F. L., Matsushita K. et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123 (25):2946-2953.
37. Kooiman J., van de Peppel W. R., van der Meer F.J. et al. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 2011;9:1652-1653.
38. Jönsson K. M., Wieloch M., Sterner G. et al. Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden. Thromb Res 2011;128:341-345.
39. Schwartz J. B. Potential effect of substituting estimated glomerular filtration rate for estimated creatinine clearance for dosing of direct oral anticoagulants. J Am Geriatr Soc 2016;64:1996-2002.
40. Instructions for the use of medicinal product for medical use Elikvis® 002007 [the Internet]. [quoted on th 1 July, 2017]. Available on: https://grls.rosminzdrav.ru/Grls_View_v2. aspx? routingGuid=3e7c7f8b-6695-432f-97f6-ead24eae7578&t=. Russian (Инструкция по применению лекарственного препарата для медицинского применения Эликвис® ЛП-002007 [Интернет]. [цитируется по 1 июль 2017 г.]. Доступно на: https:// grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3e7c7f8b-6695-432f-97f6-ead24eae7578&t=)
41. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507. DOI:10.1093/europace/euv309
42. Tan J., Liu S., Segal J. B. et al. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol 2016;17 (1):157.
43. Voskamp P. W. M., Rookmaaker M. B., Verhaar M. C. et al. Vitamin K antagonist use and mortality in dialysis patients. Nephrol Dial Transplant 2017 Aug 2. doi: 10.1093/ndt/gfx199.
44. Egshatyan L. V., Rozhinskaya L. Ya. Calcific uremic arteriolopathy (calciphylaxis). Review and case description. Nephrology and Dialysis 2015;17 (4):478-485. Russian (Егшатян Л. В., Рожинская Л. Я. Кальцифицирующая уремическая артериолопатия (кальцифилаксия). Обзор литературы и собственное наблюдение. Нефрология и диализ 2015;17 (4):478-485).
45. Bonde A. N., Lip G. Y. H., Kamper A.-L. et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study J Am Coll Cardiol 2014;64:2471-2482.
46. Limdi N. A., Beasley T. M., Baird M. F. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009;20:912-921.
47. Chan K. E., Giugliano R. P., Patel M. R. et al. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.J Am Coll Cardiol 2016;67:2888-2899.
48. Instructions for the use of medicinal product for medical use Pradaxa® 000872 [the Internet]. [quoted on th 1 July, 2017]. Available on: https://grls.rosminzdrav.ru/Grls_View_v2. aspx? routingGuid=5e6df8af-6fb4-4c1a-9aa6-f554f12b862a&t=. Russian (Инструкция по применению лекарственного препарата для медицинского применения Прадакса® ЛП-000872 [Интернет]. [цитируется по 1 июля 2017 г.]. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2. aspx?routingGuid= 5e6df8af-6fb4-4c1a-9aa6-f554f12b862a&t=)
49. Hijazi Z., Hohnloser S. H., Oldgren J. et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. Circulation 2014;129:961-970.
50. Reilly P.A., Lehr T., Haertter S. et al. The effect of dabigatran plasma concentration and patients characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. JACC 2014;63 (4):321-328.
51. Instructions for the use of medicinal product for medical use Xarelto® 15/20 mg 001457 [the Internet]. [quoted on th 1 July, 2017]. Available on: https://grls.rosminzdrav.ru/Grls_View_v2. aspx?routingGuid=082b82c0-6225-481a-a575-befc31da5d49&t=. Russian (Инструкция по применению лекарственного препарата для медицинского применения Ксарелто® 15/20 мг ЛП-001457 [Интернет]. [цитируется по 1 июля 2017 г.]. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2. aspx?ro utingGuid=082b82c0-6225-481a-a575-befc31da5d49&t=)
52. Fox K. A. A., Piccini J. P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; doi:10.1093/eurheartj/ehr342
53. Hohnloser S. H., Hijazi Z., Thomas L. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33 (22):2821-2830.
54. Connolly S.J., Eikelboom J., Joyner C., Diener H. C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364 (9):806-817.
55. Hijazi Z., Hohnloser S. H., Andersson U. et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: Insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol 2016; DOI:10.1001 /jamacardio. 2016.1170. Article
56. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016 Aug 27. pii: ehw210.
57. Pathak R., Pandit A., Karmacharya P. et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardio. 2015;115:323-327.
58. Wang X., Tirucherai G., Marbury T. C. et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with endstage renal disease on hemodialysis. J Clin Pharmacol 2016;56 (5):628-636. doi: 10.1002/jcph. 628.
59. Chang M., Yu Z., Shenker A. et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016;56:637-645.
60. Stanton B. E., Barasch N. S., Tellor K. B. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy 2017;37 (4):412-419.
61. Adi J. Klil-Drori, Laurent Azoulay, Rui Nie et al. Comparative Risk of Acute Kidney Injury with Oral Anticoagulant Use Among Patients with Nonvalvular Atrial Fibrillation. ASH 59th Annual Meeting & Exposition. https://ash.confex.com/ash/2017/web-program/Paper102858. html
62. Obrezan A. G. Difficult questions of the anticoagulant therapy in the patients with atrial fibrillation. Vestnik Aritmologii 2017;88:68-72. Russian (Обрезан А. Г. Трудные вопросы антикоагулянтной терапии у пациентов с фибрилляцией предсердий. Вестник аритмологии 2017;88:68-72.)
Рецензия
Для цитирования:
Обрезан А.Г., Земченков А.Ю. ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК КАК ОСНОВА ПОВЫШЕННОГО РИСКА РАЗВИТИЯ ГЕМОРРАГИЧЕСКИХ И ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ: МЕСТО ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ. Кардиология. 2018;58(4):60-70. https://doi.org/10.18087/cardio.2018.4.10111
For citation:
Obrezan A.G., Zemchenkov A.Yu. Chronic Kidney Disease as Basis of High Thrombotic and Bleeding Risk in Patients With Atrial Fibrillation: Place of Oral Anticoagulants. Kardiologiia. 2018;58(4):60-70. (In Russ.) https://doi.org/10.18087/cardio.2018.4.10111
Просмотров: 1885
Послать статью по эл. почте 
Оставить комментарий 